![](/images/graphics-bg.png)
Efficacy of Transdermal Oxybutynin in the Treatment of Overactive Bladder Syndrome: Does It Make Sense Using It in 2017?
المؤلفون المشاركون
Vozmediano-Chicharro, Raúl
Madurga, Blanca
Blasco, Pedro
المصدر
العدد
المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-7، 7ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2018-07-29
دولة النشر
مصر
عدد الصفحات
7
التخصصات الرئيسية
الملخص EN
Objectives.
Evaluation of changes in symptoms among patients with overactive bladder syndrome treated with transdermal oxybutynin and tolerability after 12 months of follow-up.
Methods.
This was a multicenter, retrospective, single-cohort, observational study.
Changes in symptoms were evaluated primarily with a 3-day voiding diary.
Results were compared to baseline.
Subgroup analyses were performed in patients previously treated for OAB or not and aged < 65 years versus ≥65 years.
Results.
Clinical records of 105 patients were examined; 92.4% were women.
At 12 months, 58 patients continued to receive transdermal oxybutynin.
Changes in symptoms according to the voiding diary were evaluated in 47 patients.
Significant improvements from baseline were observed in urinary frequency (−2.6 voids/24 hours (95% CI: −3.5; −1.8), p<0.001); daily number of urgent episodes (−4.7 episodes/day (95% CI: −6.1; −3.6), p<0.001); and urge incontinence (−1.9 episodes/day (95% CI: −2.9; −1.3), p<0.001).
No statistically significant differences were found in subgroup analyses.
In total, 38.1% of patients had adverse events, primarily in the application site (27.6%).
No severe systemic adverse events occurred.
Only 6 patients (5.7%) reported dry mouth.
Conclusions.
Improved symptoms and good tolerability observed after 1 year of treatment with transdermal oxybutynin shows that it currently has a place in the treatment of OAB patients.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Vozmediano-Chicharro, Raúl& Madurga, Blanca& Blasco, Pedro. 2018. Efficacy of Transdermal Oxybutynin in the Treatment of Overactive Bladder Syndrome: Does It Make Sense Using It in 2017?. Advances in Urology،Vol. 2018, no. 2018, pp.1-7.
https://search.emarefa.net/detail/BIM-1123019
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Vozmediano-Chicharro, Raúl…[et al.]. Efficacy of Transdermal Oxybutynin in the Treatment of Overactive Bladder Syndrome: Does It Make Sense Using It in 2017?. Advances in Urology No. 2018 (2018), pp.1-7.
https://search.emarefa.net/detail/BIM-1123019
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Vozmediano-Chicharro, Raúl& Madurga, Blanca& Blasco, Pedro. Efficacy of Transdermal Oxybutynin in the Treatment of Overactive Bladder Syndrome: Does It Make Sense Using It in 2017?. Advances in Urology. 2018. Vol. 2018, no. 2018, pp.1-7.
https://search.emarefa.net/detail/BIM-1123019
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1123019
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)